- Home
- GAIN vs EYPT Comparison
GAIN vs EYPT Comparison
Compare GAIN & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- EYPT
- Stock Information
- Founded
- GAIN 2005
- EYPT 1987
- Country
- GAIN United States
- EYPT United States
- Employees
- GAIN N/A
- EYPT N/A
- Industry
- GAIN Finance: Consumer Services
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- GAIN Finance
- EYPT Industrials
- Exchange
- GAIN Nasdaq
- EYPT Nasdaq
- Market Cap
- GAIN 497.3M
- EYPT 427.9M
- IPO Year
- GAIN 2005
- EYPT 2005
- Fundamental
- Price
- GAIN $13.38
- EYPT $5.26
- Analyst Decision
- GAIN Hold
- EYPT Strong Buy
- Analyst Count
- GAIN 2
- EYPT 8
- Target Price
- GAIN $13.75
- EYPT $25.71
- AVG Volume (30 Days)
- GAIN 114.8K
- EYPT 738.5K
- Earning Date
- GAIN 05-07-2025
- EYPT 03-05-2025
- Dividend Yield
- GAIN 7.18%
- EYPT N/A
- EPS Growth
- GAIN N/A
- EYPT N/A
- EPS
- GAIN 1.92
- EYPT N/A
- Revenue
- GAIN $89,176,000.00
- EYPT $43,273,000.00
- Revenue This Year
- GAIN $5.92
- EYPT N/A
- Revenue Next Year
- GAIN $10.25
- EYPT N/A
- P/E Ratio
- GAIN $7.10
- EYPT N/A
- Revenue Growth
- GAIN 6.78
- EYPT N/A
- 52 Week Low
- GAIN $12.46
- EYPT $5.34
- 52 Week High
- GAIN $14.85
- EYPT $23.65
- Technical
- Relative Strength Index (RSI)
- GAIN 47.29
- EYPT 32.55
- Support Level
- GAIN $13.52
- EYPT $5.87
- Resistance Level
- GAIN $13.68
- EYPT $6.69
- Average True Range (ATR)
- GAIN 0.18
- EYPT 0.43
- MACD
- GAIN 0.01
- EYPT -0.08
- Stochastic Oscillator
- GAIN 53.28
- EYPT 3.52
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to (i) achieve and grow current income by investing in debt securities of established businesses. (ii) provide our stockholders with long-term capital appreciation in the value of our assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.